Literature DB >> 15224492

Rheumatoid arthritis: symptoms, diagnosis, and management.

Lynda Martin1.   

Abstract

Rheumatoid arthritis is the most common inflammatory joint disease and a major cause of disability, morbidity, and mortality. It occurs worldwide, affecting approximately one per cent of adults. Inflammation of the synovial membrane surrounding a joint leads to swollen, tender, and stiff joints. This may be accompanied by fatigue, weight loss, anxiety, and depression. Nursing management goals should include the relief of symptoms, preservation of joint function, prevention of joint damage and deformity, maintenance of an acceptable lifestyle, and patient education. To achieve these aims the nurse should play a pivotal role within the multidisciplinary team, ensuring the highest quality of care.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15224492

Source DB:  PubMed          Journal:  Nurs Times        ISSN: 0954-7762


  4 in total

1.  Intravenous anesthetic ketamine attenuates complete Freund's adjuvant-induced arthritis in rats via modulation of MAPKs/NF-κB.

Authors:  Hui Lin; Zhe Wang; Jinmei Shen; Junmei Xu; Hui Li
Journal:  Inflamm Res       Date:  2018-11-30       Impact factor: 4.575

2.  DC32, a Dihydroartemisinin Derivative, Ameliorates Collagen-Induced Arthritis Through an Nrf2-p62-Keap1 Feedback Loop.

Authors:  Menglin Fan; Yanan Li; Chunhua Yao; Xiufeng Liu; Jihua Liu; Boyang Yu
Journal:  Front Immunol       Date:  2018-11-27       Impact factor: 7.561

Review 3.  Exploring the role of cathepsin in rheumatoid arthritis.

Authors:  Tapan Behl; Swati Chadha; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Rajwinder Kaur; Saurabh Bhatia; Ahmed Al-Harrasi; Sridevi Chigurupati; Ahmed Alhowail; Simona Bungau
Journal:  Saudi J Biol Sci       Date:  2021-09-13       Impact factor: 4.219

Review 4.  Tertiary Lymphoid Structures: Autoimmunity Goes Local.

Authors:  Elena Pipi; Saba Nayar; David H Gardner; Serena Colafrancesco; Charlotte Smith; Francesca Barone
Journal:  Front Immunol       Date:  2018-09-12       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.